Abstract
2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) is an analog of the quinoxalinedione antagonists to the non-N-methyl-D-aspartate (non-NMDA) glutamate receptor. NBQX is a potent and selective inhibitor of binding to the quisqualate subtype of the glutamate receptor, with no activity at the NMDA and glycine sites. NBQX protects against global ischemia, even when administered 2 hours after an ischemic challenge.
MeSH terms
-
Animals
-
Aspartic Acid / analogs & derivatives
-
Aspartic Acid / pharmacology
-
Brain Ischemia / drug therapy*
-
Cerebral Cortex / drug effects
-
Cerebral Cortex / physiology*
-
Hippocampus / drug effects
-
Hippocampus / physiology*
-
Hippocampus / physiopathology
-
Ibotenic Acid / analogs & derivatives
-
Ibotenic Acid / pharmacology
-
In Vitro Techniques
-
Kainic Acid / pharmacology
-
N-Methylaspartate
-
Neurons / drug effects
-
Neurons / physiology
-
Oxadiazoles / pharmacology
-
Pyramidal Tracts / drug effects
-
Pyramidal Tracts / physiology*
-
Pyramidal Tracts / physiopathology
-
Quinoxalines / metabolism
-
Quinoxalines / pharmacology
-
Quinoxalines / therapeutic use*
-
Quisqualic Acid
-
Rats
-
Receptors, Glutamate
-
Receptors, Kainic Acid
-
Receptors, Neurotransmitter / drug effects
-
Receptors, Neurotransmitter / metabolism
-
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid
Substances
-
Oxadiazoles
-
Quinoxalines
-
Receptors, Glutamate
-
Receptors, Kainic Acid
-
Receptors, Neurotransmitter
-
2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline
-
Ibotenic Acid
-
Aspartic Acid
-
N-Methylaspartate
-
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid
-
Quisqualic Acid
-
Kainic Acid